Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:

NCT ID: NCT00711139 Completed - Alzheimer's Disease Clinical Trials

Long-term Safety and Tolerability of AFFITOPE AD01

Start date: June 2008
Phase: N/A
Study type: Observational

The purpose of this study is to assess the long-term tolerability and -safety of AFFITOPE AD01 applied during AFFiRiS 001

NCT ID: NCT00710684 Completed - Alzheimer's Disease Clinical Trials

A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease

Start date: July 1, 2008
Phase: Phase 2
Study type: Interventional

The study is designed to investigate the safety and efficacy of SB-742457 when added to stable donepezil treatment in subjects with mild-to-moderate Alzheimer's disease.

NCT ID: NCT00708552 Completed - Alzheimer's Disease Clinical Trials

Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease

Start date: July 4, 2008
Phase: Phase 2
Study type: Interventional

The study is designed to investigate the efficacy, safety and tolerability of SB-742457 versus placebo in subjects with mild-to-moderate Alzheimer's disease. SB-742457 is an experimental treatment which increases the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's disease.

NCT ID: NCT00702780 Completed - Alzheimer's Disease Clinical Trials

Progression Delaying Effect of Escitalopram in Alzheimer's Disease

ESAD
Start date: November 2008
Phase: N/A
Study type: Interventional

This study aimed to test whether escitalopram would slow the brain atrophy in patients with mild to moderate AD over the 52-week period.

NCT ID: NCT00702143 Completed - Clinical trials for Mild Cognitive Impairment

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Start date: June 2008
Phase: Phase 2
Study type: Interventional

Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).

NCT ID: NCT00698165 Completed - Alzheimer's Disease Clinical Trials

Observational Study on Costs and Caregiver Burden in Alzheimer's Disease

Start date: June 2007
Phase: N/A
Study type: Observational

Objective of study is to assess the costs of care, objective and subjective caregiver burden and quality of life in relation to disease severity measured by cognitive function, ADL capabilities and presence of behavioral disturbances in Alzheimer's disease

NCT ID: NCT00692705 Completed - Alzheimer´s Disease Clinical Trials

Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid

PET
Start date: January 2008
Phase: Phase 1
Study type: Interventional

The study is carried out in order to investigate if [11C]AZD2995, compared to [11C]AZD2184, is a more suitable PET ligand for in vivo imaging of β amyloid depositions in the human brain. In the study the two PET ligands will be examined in both healthy volunteers and patients with Alzheimer's Disease.

NCT ID: NCT00692588 Completed - Alzheimer's Disease Clinical Trials

MRI to Measure Treatment With Antibiotics in Alzheimer's Disease

DARAD-MRI
Start date: June 2008
Phase: N/A
Study type: Observational

Objectives: To study the changes in brain structure and function using MRI scans in patients treated for Alzheimer's disease. Methods: A pilot study of treating Alzheimer's disease with antibiotics showed some promise that this treatment could delay the deterioration of the mind with this disease. This study is being replicated on a larger scale, providing a more definitive answer to this question. In addition to looking at changes of the mind (through cognitive tests), we would like to use MRI scans in these patients before and after treatment to study the structural changes and the chemical changes in the brain. This would provide a non-invasive look at the bran processes that protect the brain from the effect of Alzheimer's as well as confirming that the disease has been modified with treatment. Impact: The novel treatment of Alzheimer's with antibiotics has provided a potential breakthrough in the field. In addition to verifying changes in the brain, MRI scans can observe HOW this process could occur, thus opening doors to other new treatments for Alzheimer's and perhaps even cures.

NCT ID: NCT00692510 Completed - Alzheimer's Disease Clinical Trials

Drug Interaction Study Between AZD3480 and Cytochrome P450

Cocktail
Start date: November 2007
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate if AZD3480 inhibits Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 activity.

NCT ID: NCT00689637 Completed - Alzheimer's Disease Clinical Trials

Drug Interaction Study Between AZD3480 and Warfarin

DDI
Start date: September 2007
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate if AZD3480 and warfarin interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.